BioNTech US, Inc. (NTGN)


Stock Price Forecast

May 5, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading BioNTech US, Inc. chart...

About the Company

BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.

Sector

Health Technology

Industry

Biotechnology

Employees

71

Exchange

NASDAQ

Website

https://neontherapeutics.com/

$M

Total Revenue

71

Employees

$86M

Market Capitalization

-1.07

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NTGN News

A Look Into BioNTech Inc's Price Over Earnings

10mon ago, source: Hosted on MSN

In the current session, BioNTech Inc. (NASDAQ:BNTX ... Chinese Tech Companies Forced To Think Outside The Box To Overcome US Chip Ban In The Race For AI Supremacy Compared to the aggregate ...

BioNTech Gains as Vaccine Maker Has Profit on Cost-Sharing

4mon ago, source: Hosted on MSN

The US depositary ... vaccine rival Moderna Inc. have both reined in expectations for Covid-related sales in recent weeks. The pandemic shots were both Moderna’s and BioNTech’s first products ...

COVID Vaccines Reduce Risk of Heart Failure, Clots

13h ago, source: WebMD

People who got COVID-19 vaccines had a reduced risk of heart failure, compared to people who didn’t get vaccinated, according ...

Pfizer/BioNTech dose first US patients with COVID-19 vaccine

3y ago, source: pharmaphorum

Pfizer and its development partner BioNTech have begun dosing the first people in the US with a potential COVID-19 vaccine, as part of their ongoing phase 1/2 clinical trial. The companies ...

BioNTech Announces Planned Retirement of Sean Marett

11d ago, source:

Sean Marett joined BioNTech as a member of the Management Board in 2012. He has played a crucial role in the Company’s growth and global expansion, overseeing two key areas: business development and ...

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

7d ago, source:

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also ...

COVID-19 Vaccine Update – It’s All Eyes on the FDA and BioNTech/Pfizer Inc.

3y ago, source: FXEmpire.com

Approval would mean that BioNTech/Pfizer Inc. will be able to begin distributing vaccines as early as the weekend. Unfortunately, supply chain issues have meant that vaccine production for the ...

Moderna, BioNTech Stocks Rise on New mRNA Possibilities

7d ago, source: Wall Street Journal

Shares of Moderna and BioNTech rose on Monday after two tantalizing morsels hinted at their potential for attacking cancer. Cancer treatment is one of the pharmaceutical industry’s biggest ...

BioNTech SE ADR BNTX

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pfizer, BioNTech seek US okay for Omicron BA.4/BA.5 booster

1y ago, source: pharmaphorum

According to Pfizer/BioNTech, preclinical data has shown that a booster dose with the BA.4/BA.5-adapted bivalent vaccine generated a strong neutralising antibody response against Omicron BA.1, BA ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...